1 XMR = $596.01

Please login

Region:

Buy
Tesamorelin 10mg
0.15 XMR
(≈ $89.40)
(0)
(1)
Rating N/A (0 reviews)
Stock
Unlimited stock
Location
Australia
Delivery
  • Domestic shipping - 0 XMR
Payment
  • Direct payment (XMR)
  • Multisig escrow (XMR)


Rating 5.00 (12 reviews)
Member since Feb 2025

Tesamorelin 10mg

Description

Also known as: Egrifta, TH9507, Growth Hormone Releasing Factor
An FDA-approved GHRH analog specifically indicated for reducing visceral adiposity in HIV patients. Provides targeted fat loss while maintaining lean mass.
Primary Mechanisms
1. GHRH Receptor Binding
2. Pulsatile GH Stimulation
3. IGF-1 Elevation
4. Targeted Lipolysis

Category: Health

Tags: research, peptide, . GHRH, GH Stimulation, IGF-1, Targeted Lipolysis

Trust rating: Green
This seller offers multisig escrow or has bond insurance, meaning that buyers can request a refund in the case of a dispute. Note: Buyers must select multisig escrow or bond insurance when making the order. This trust rating does not apply to direct payment orders, which go directly to the seller and cannot be refunded. Escrow guide Bonds guide

Published on: October 30, 2026

Views: 4

Legal Notice: Buyers and sellers are responsible for complying with all applicable laws in their jurisdictions. XmrBazaar does not verify legality and assumes no liability. Peer-to-peer cash-for-crypto trades are permitted if not conducted as a business and are compliant with local laws; otherwise, sellers must hold any required licenses or registrations. Listings involving fraud, violence, child exploitation, or other clearly illegal goods or services are strictly prohibited and will be removed once identified. Users are encouraged to report unlawful listings.

N/A stars overall - 0 reviews for this listing
No reviews yet
0 comments for this listing
No comments yet

About the trader

5.00 (12 reviews)
Member since February 2025
About me

Researcher Health Products

Links

N/A

PGP key
-----BEGIN PGP PUBLIC KEY BLOCK-----
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=MOjw
-----END PGP PUBLIC KEY BLOCK-----